Remarkably, Meflin has the capacity to suppress αSMA expression (myofibroblastic differentiation) in CAFs as well as ECM remodeling, a crucial process for cancer progression, which might give some insight into the functionality of tumor-suppressive CAFs and how they inhibit tumor growth. Here, ACTA1 is linked to cancer.